Researchers used two placebo trials to estimate a difference between Wegovy tablets and injections [1]. Our guide to oral and injected semaglutide doses explains what each trial measured. No participants were randomly assigned between the two formulations in this analysis.
How the comparison worked
OASIS 4 tested the 25 mg daily tablet against oral placebo. STEP 1 tested the 2.4 mg weekly injection against injectable placebo. Researchers used the placebo arms as a common reference [1]. The analysis depends on how comparable the trials and their participants were.
What the numbers show
The estimated weight-loss difference favored the injection by 1.01 percentage points [1]. The 95% confidence interval ran from −1.61 to 3.63 points. A second analysis assuming adherence favored the injection by 0.55 points, with a 95% confidence interval from −2.25 to 3.35. Both intervals leave room for a small advantage in either direction.
Novo Nordisk, the maker of Wegovy, funded this indirect comparison. A price comparison for GLP-1 pills and injections is useful only when the products and terms are clear. This analysis does not establish therapeutic equivalence or extend to other formulations.